Atara biotherapeutics, inc. (ATRA)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'12
Operating activities
Net loss

-73,509

-78,496

-71,895

-74,328

-66,257

-80,012

-58,361

-50,883

-41,443

-35,313

-31,096

-27,428

-25,654

-18,235

-25,373

-18,880

-16,561

-21,248

-11,868

-14,945

-9,160

-10,527

-5,919

-4,511

-7,049

-4,110

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

12,644

12,074

12,152

15,201

12,269

9,553

9,251

7,999

7,014

6,097

6,000

5,656

5,347

1,656

5,268

5,136

4,724

2,964

2,234

2,570

2,483

5,773

484

527

3,317

292

Depreciation and amortization expense

1,900

1,900

1,800

1,800

1,600

1,400

1,200

767

333

322

250

222

206

173

131

64

15

27

10

5

6

2

2

1

1

-

Amortization (accretion) of investment premiums (discounts)

-42

153

360

359

458

546

583

539

217

-125

-148

-158

-301

229

-517

-1,008

-1,286

-1,751

-834

-522

-358

-

-

-

-

-

Non-cash operating lease expense

364

-

-

-

331

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

0

86

61

64

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Asset retirement obligation accretion expense

19

18

18

18

17

17

16

16

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

In-process research and development acquired from Amgen

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,768

Loss on foreign exchange

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

38

-42

-

-

-

-

-

-

-

-

-

Investment premium amortization, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16

-

Interest accrued on notes receivable from stockholder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1

1

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

1,888

2,202

-484

-2,154

1,434

3,425

378

1,772

189

-341

400

924

-199

140

-214

-488

1,304

-1,747

-800

2,233

1,081

1,279

-297

308

-44

35

Operating lease assets

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

209

-14

-53

-217

-38

89

123

262

-160

0

-76

-644

718

0

1

11

-18

11

26

-7

31

3

35

0

-1

39

Accounts payable

-590

2,686

-1,122

-23

2,672

-2,074

323

1,912

-2,119

2,164

-254

719

-466

-2,037

1,228

1,339

451

-408

251

808

354

-127

-8

-450

421

121

Accrued compensation

-5,030

1,809

5,075

363

-3,177

1,564

3,796

964

-1,352

345

2,057

653

-1,136

589

1,021

798

-1,287

1,062

638

402

-703

725

141

160

-132

51

Accrued research and development expenses

-514

2,169

1,033

-1,055

-13,016

15,407

-2,858

325

2,330

196

1,739

-35

-302

-2,701

1,310

-631

-682

2,575

-2,787

3,590

910

-

-

-

-

-

Other current liabilities

-169

1,442

-178

914

-2,572

428

-482

2,001

544

792

944

-19

179

-218

198

-434

669

30

-2,984

3,018

229

-436

85

-202

557

120

Operating lease liabilities

-153

-244

-188

-38

-261

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term liabilities

-

-

-

-

-

280

26

13

53

37

307

53

10

-22

-91

373

138

4

-2

14

13

-

-

-

-

-

Income tax payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-92

7

Net cash used in operating activities

-67,044

-58,690

-52,147

-54,589

-70,200

-57,419

-48,097

-39,434

-34,822

-24,938

-20,229

-20,301

-22,034

-21,164

-15,582

-10,788

-12,491

-11,392

-12,900

-6,242

-6,622

-4,957

-4,092

-4,662

-2,917

-825

Purchases of short-term investments

56,851

123,043

129,598

10,162

7,427

63,868

44,974

65,180

292,467

23,622

40,442

60,407

51,988

52,649

66,273

55,043

130,963

94,386

174,065

56,529

54,796

-

-

2,573

22,414

-

Sales of short-term investments

-

-

-

-

-

-

-

-

35,890

-

6,506

24,255

27,456

55,135

92,266

19,376

75,866

-

-

-

-

-

-

-

-

-

Maturities of short-term investments

-

-

-

-

-

-

-

-

26,468

-

46,745

51,589

63,760

21,297

9,429

51,471

66,849

-

-

-

-

-

-

-

-

-

Proceeds from maturities and sales of short-term investments

97,157

126,882

72,503

61,057

75,819

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

41,368

-

-

-

-

-

Purchases of property and equipment

1,333

2,712

1,487

738

796

4,169

4,499

7,449

19,808

9,697

6,194

3,135

1,206

995

386

748

891

271

14

0

5

36

5

4

1

9

Net cash provided by investing activities

38,973

1,127

-58,517

50,253

67,596

46,068

11,437

-3,877

-249,917

42,970

6,615

12,302

38,022

22,788

35,036

15,056

10,861

-19,419

-152,887

-34,388

-13,433

-56,935

-1,436

-2,577

-22,415

-9

Financing activities
Proceeds from sale of common stock in underwritten offerings, net

-

-

-

-

-

0

0

0

293,290

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock through ATM facilities, net

24,277

35,099

5,000

7,630

0

-

-

-

-

-50

9,880

9,326

0

-

-

-

-

-

193,989

-42

69,487

-

-

-

-

91

Proceeds from employee stock awards

1,330

2,491

183

1,929

2,747

6,163

3,671

8,671

6,186

754

0

495

0

350

221

15

14

-

-

-

-

-

-

-

-

-

Taxes paid related to net share settlement of restricted stock units

1,395

0

25

2,095

4,575

10

4,062

67

3,364

6

10

15

326

19

22

21

32

-

-

-

-

-

-

-

-

-

Principal payments on finance lease obligations

90

141

110

137

98

132

124

171

101

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Other financing activities, net

-165

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of notes receivable from stockholder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

300

37

-

Proceeds from sale of convertible preferred stock, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-19

0

0

13,500

5,000

Net cash provided by (used in) financing activities

23,957

37,449

145,936

7,327

-1,926

6,021

-515

56,019

296,011

698

9,870

9,806

-326

331

199

-6

-18

185

194,064

-4,510

69,487

58,086

-548

-736

13,471

5,041

Proceeds from sale of unvested restricted stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

Offering costs incurred

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

54

Effect of exchange rates on cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

38

-42

-

-

-

-

-

-

-

-

-

Decrease in cash, cash equivalents and restricted cash

-4,114

-20,114

35,272

2,991

-4,530

-5,330

-37,175

12,708

11,272

18,730

-3,744

1,807

15,662

1,955

19,657

4,300

-1,690

-30,720

28,277

-45,140

49,432

-3,806

-6,076

-7,975

-11,861

4,207

Non-cash investing and financing activities
Property and equipment purchases included in accounts payable and other accrued liabilities

1,098

-423

226

-193

666

-2,394

-1,105

973

4,105

7,058

562

2,295

207

223

-374

503

0

-

-

-

-

-

-

-

-

-

Finance lease assets obtained in exchange for lease obligations

281

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued costs related to ATM facilities

112

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Receivable for options exercised

0

-

-

-127

151

-

-

-10

10

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Capitalized lease obligations

-

-

-

-

-

0

0

0

441

-

-

-

286

-

0

0

0

-

-

-

-

-

-

-

-

-

Asset retirement costs

-

-

-

-

-

0

0

0

88

580

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest capitalized during construction period for build-to-suit lease arrangement

-

-

-

-

-

0

0

0

77

131

38

95

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of Series A-1 convertible preferred stock to Amgen in exchange for license

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,765

Change in obligation to issue Series A-1 convertible preferred stock to Amgen

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,003

Issuance of common stock upon vesting of stock awards

-

-

-

-

-

-

-

-

-

-

-

-

-

0

20

20

20

20

20

20

20

25

20

25

20

-

Change in long-term liabilities related to non-vested stock awards

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-20

-20

-20

-20

-20

-20

-20

-25

-20

-25

-20

-

Supplemental cash flow disclosure
Cash paid for interest

17

7

12

31

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for income taxes

0

-

-

-

0

-

-

-

-

-

-

-

2

0

7

0

3

1

0

0

2

0

0

0

70

9

Offering costs in anticipation of initial public filing included in other accrued liabilities and accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

510

-